3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
pembrolizumab
47
Carboplatin
35
Paclitaxel
28
Specimen Handling
20
Cyclophosphamide
17
Capecitabine
16
Magnetic Resonance Spectroscopy
15
sacituzumab govitecan
13
Gemcitabine
13
Biopsy
13
Taxes
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
olaparib
8
Doxorubicin
8
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Immunoglobulin G
4
Fulvestrant
4
Epirubicin
4
Drug Therapy
4
Bevacizumab
4
veliparib
3
toripalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
SGN-LIV1A
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled